DRG Market Assessment reports

LaunchTrends: Anoro Ellipta Wave 3 is the third of a three-wave report series designed to track the post-launch awareness, trial, and usage of Anoro Ellipta among pulmonologists for the treatment…

How Will the Complex Interplay Between Efficacy, Safety, and Delivery Impact Retinal Specialists’ Preferences for and Payers’ Acceptance of Current and Emerging Therapies? Diabetic macular…

Which Key Attributes Will Drive Physician Prescribing and Formulary Inclusion of Current and Emerging PAH Therapies? Pulmonary arterial hypertension (PAH) is a severe, progressive, debilitating…

Payer and Physician Perspectives on the Role of New Biologics and Biosimilars for Moderate to Severe Inflammatory Bowel Disease Moderate to severe inflammatory bowel disease (IBD) patients who…

Where Are the Remaining Areas of Opportunity for Emerging Non-TNF Biologics and Oral Agents in the Increasingly Crowded Psoriatic Arthritis Market? The availability of tumor necrosis factor…

Physician and Payer Attitudes and the Impact of the Aging Population Aging is considered a new healthcare challenge globally, and Alzheimer’s disease (AD) is one of the most debilitating…

Psoriatic arthritis (PsA) is an inflammatory joint disease that is highly comorbid with psoriasis, and characterized by pain, stiffness, and/or swelling in the joints, ligaments, and tendons. In…

Physician and Payer Perspectives as Smoking and Pollution Perils Point to Sharply Increasing COPD Incidence Chronic obstructive pulmonary disease (COPD) has become a leading case of mortality…

TreatmentTrends®: Prostate Cancer Q2 2015 (US) is part of a series of reports that examine current trends in the management of localized to metastatic prostate cancer from the perspective of both…

Hepatitis C virus (HCV) chronic infections are a leading cause of advanced liver disease and hepatocellular carcinoma and are a common indication for liver transplantation. The late 2013 FDA…

LaunchTrends: Cosentyx (US) is a three-wave syndicated report series that specifically tracks the introduction of Novartis’s Cosentyx (secukinumab), a potent, subcutaneous IL-17 inhibitor…

Amid Significant Unmet Need, What Magnitude of Efficacy and Safety Do Endocrinologists and Payers Expect of New and Emerging Therapies? The evidence demonstrating the serious physical, economic…